SCHEMBL3727664

SCHEMBL3727664

CCCCOc1ccccc1C(=O)Nc1ccc(CC(=O)OCC(C(=O)OCC)(C(=O)OCC)c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
MEN1 O00255 3/20 0.47
MAPT P10636 8/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
MAPK1 P28482 3/20 0.46
ALDH1A1 P00352 1/20 0.46
MLNR O43193 1/20 0.46
NR1I2 O75469 1/20 0.46
NR3C1 P04150 1/20 0.46
PGR P06401 1/20 0.46
ADRB2 P07550 1/20 0.46
CHRM2 P08172 1/20 0.46
ADRB1 P08588 1/20 0.46
HTR1A P08908 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
CHRM1 P11229 1/20 0.46
DRD2 P14416 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46
CHRM3 P20309 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3725285 0.89 MAPT (0.46) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3729086 0.89 MAPT (0.52) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3726154 0.89 KMT2A (0.46) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3728909 0.86 F2R (0.48) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3723403 0.85 KMT2A (0.44) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3733236 0.84 MAPT (0.48) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3727712 0.83 SMN1; SMN2 (0.50) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3728899 0.83 SMN1; SMN2 (0.47) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3727303 0.83 MAPT (0.47) KMT2AMEN1MAPTSMN1; SMN2MAPK1
SCHEMBL3723408 0.81 SMN1; SMN2 (0.48) KMT2AMEN1MAPTSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. 2010-06-24 US claimed
US-20050075367-A1 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-04-07 US claimed
EP-1479666-A1 ESTER COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-11-24 EP claimed
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. 2010-06-24 US disclosed
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. 2010-06-24 US disclosed
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. 2010-06-24 US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 US disclosed
US-20050075367-A1 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-04-07 US disclosed
EP-1479666-A1 ESTER COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075367-A1 Ester compound and medicinal use thereof LIPC, CES1, MTTP KMT2A 2890/4885MEN1 2645/4885MAPT 4387/4885
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF LIPC, CES1, MTTP KMT2A 3106/4885MEN1 2283/4885MAPT 4163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.